Drug Research
NexImmune Raises $23 Million to Advance Endogenous Cellular ImmunoTherapy into Clinical Development
NexImmune, an emerging leader in the field of antigen-directed immunotherapy, announced the closing of a Series A financing co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital, along with significant participation from Piedmont Capital Partners. ...
Drug Research
Idorsia forms research collaboration with Roche in the field of cancer immunotherapy
Idorsia Ltd announced that it has entered into a research collaboration that provides Roche with an exclusive option right to develop and market first-in-class compounds for a promising new approach in the field of cancer immunotherapy. ...
Drug Research
NorthSea Therapeutics Secures €25 Million Funding for Clinical Development of Promising NASH Drug
NorthSea Therapeutics B.V. , a newly established Dutch biotech company, announced the completion of a €25m Series A funding for the development of icosabutate, a structurally engineered fatty acid (‘SEFA’) as a novel, oral approach for the treatment of...
Drug Research
Agendia Collaborates with Prestigious Cancer Center, Institut Curie, for MammaPrint® BluePrint® Breast Cancer Kit Co-Validation Study
Agendia, a world leader in personalized medicine and molecular cancer diagnostics, and Institute Curie in Paris, France, a leading player in the fight against cancer. Announce a co-validation partnership for Agendia’s new in vitro diagnostic (IVD)...
Drug Research
Torque Launches Platform to Develop New Class of Deep Primed Immune Cell Therapies
Torque, an immuno-oncology company developing Deep Primed cell therapies that direct and evoke immune responses in the tumor microenvironment, announced the launch of its technology platform to create a new class of immune cell therapeutics to treat cancer, financed...
Drug Research
Eisai: Antiepileptic Drug Fycompa Regularly Available Again in Germany from December
Eisai Co., Ltd. has announced that its German sales company Eisai GmbH and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) have agreed on a reimbursement price for Eisai's antiepileptic drug (AED) Fycompa (perampanel). As...
Drug Research
ANTABIO Raises € 7.3M Series A Financing to Develop Novel Treatments against Drug-Resistant Gram-Negative Infections
Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today the completion of a €7.3M series. A financing with subscriptions from investment funds iXO Private Equity, IRDI SORIDEC Gestion,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
